XML 50 R35.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Interests in subsidiaries | 12 Months Ended
--- | ---
Jun. 30, 2022
Investments accounted for using equity method [abstract] |
Interests in subsidiaries | Note 30. Interests in subsidiaries The consolidated financial statements incorporate the assets, liabilities and results of the following subsidiaries in accordance with the accounting policy described in note 2:
|  |  |  | Ownership interest |
Name |  | Principal place of business / Country of incorporation |  | 2022 % |  |  | 2021 % |
Kazia Laboratories Pty Ltd |  | Australia |  |  | 100.00 | % |  |  | 100.00 | %
Kazia Research Pty Ltd |  | Australia |  |  | 100.00 | % |  |  | 100.00 | %
Kazia Therapeutics Inc. |  | United States of America |  |  | 100.00 | % |  |  | 100.00 | %
Glioblast Pty Ltd |  | Australia |  |  | 100.00 | % |  |  | 100.00 | %
Kazia Therapeutics (Hong Kong) Limited |  | Hong Kong |  |  | 100.00 | % |  |  | 100.00 | %

X
- Definition The disclosure of interests in subsidiaries. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2021-01-01 -Paragraph 2 -Subparagraph b -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_2_b_i&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_InvestmentsAccountedForUsingEquityMethodAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration